Q-omics provides the consensus-scored ATP5PBP2 profile across patient tissues and cancer cell-line models. ATP5PBP2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ATP5PBP2 is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, ATP5PBP2 RNA expression shows 5,898 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, KICH, and STAD as cancer lineages where ATP5PBP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP5PBP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP5PBP2 survival associations across molecular data types. ATP5PBP2 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP5PBP2 RNA expression–survival associations across cancer types. High ATP5PBP2 expression shows unfavorable associations in UCEC, HNSC, PAAD, KICH and ACC, but favorable associations in BLCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .010). Together, the overview and detailed table identify UCEC as the clearest survival context for ATP5PBP2 RNA expression.
This table summarizes ATP5PBP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ATP5PBP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP5PBP2 shows lower tumor expression in KICH, KIRP and KIRC and higher tumor expression in UCEC. The KICH box plot shows higher ATP5PBP2 RNA expression in normal versus tumor tissue (log2 FC = −0.106, t-test p < 0.001).
This table shows molecular features associated with ATP5PBP2 in patient tissues and cancer cell lines. In patient samples, ATP5PBP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
